Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talnetant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 known ✓ | P29371 | 20/20 | 1.00 |
| ▸ | TACR2 | P21452 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | ATM | Q13315 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talnetant SCHEMBL29604291 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL29390363 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL74220 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL6449764 | 1.00 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL29407582 | 0.99 | TACR3 (0.98) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL5154081 | 0.99 | TACR3 (0.98) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL27458094 | 0.99 | TACR3 (0.98) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL5154084 | 0.98 | TACR3 (0.96) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14094490 | 0.93 | TACR3 (0.88) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14015177 | 0.92 | TACR3 (0.84) | TACR3TACR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3470 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704271-B1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250270330-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. | 2025-08-28 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4514351-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | Kallyope, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| US-20250057830-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-02-20 | — | — | US | claimed |
| CN-119403555-A | Treatment of headache disorders using NK3 modulators | 卡尔优普公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-12083109-B2 | Neurokinin antagonists and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-09-10 | — | — | US | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| US-20020038029-A1 | Reacting 3-hydroxy-2-phenylquinoline-4-carboxylic acid, in solvent with riethyl amine, cooling,adding thionyl chloride; adding phenyl propylamine, heating to form (-)-(S)-N( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide | SMITHKLINE BEECHAM CORPORATION | 2002-03-28 | — | — | US | claimed |
| US-6335448-B1 | NK-3 RECEPTOR ANTAGONISTS ARE USEFUL IN TREATING THE SYMPTOMS OF COPD AND URINARY INCONTINENCE IN MAMMALS. | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | claimed |
| WO-2001095939-A1 | NOVEL SOLID DISPERSION COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| EP-1017676-A1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| EP-0940391-A2 | Quinoline derivatives as tachykinin NK3 receptor antagonists | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1999-09-08 | — | — | EP | claimed |
| WO-1999014196-A1 | METHOD FOR THE SYNTHESIS OF QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-25 | — | — | WO | claimed |
| EP-0804419-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1997-11-05 | — | — | EP | claimed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | claimed |